Artemether-lumefantrine versus chloroquine for the treatment of uncomplicated Plasmodium knowlesi malaria : an open-label randomized controlled trial CAN KNOW
Background: Plasmodium knowlesi is reported increasingly across Southeast Asia and is the most common cause of malaria in Malaysia. No randomized trials have assessed the comparative efficacy of artemether-lumefantrine (AL) for knowlesi malaria. Methods: A randomized controlled trial was conducted i...
Main Authors: | Grigg, Matthew J., William, Timothy, Barber, Bridget E., Rajahram, Giri S., Menon, Jayaram, Schimann, Emma, Wilkes, Christopher S., Patel, Kaajal, Chandna, Arjun, Price, Ric N., Yeo, Tsin Wen, Anstey, Nicholas M. |
---|---|
Other Authors: | Lee Kong Chian School of Medicine (LKCMedicine) |
Format: | Journal Article |
Language: | English |
Published: |
2020
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/142353 |
Similar Items
-
Age-related clinical spectrum of Plasmodium knowlesi malaria and predictors of severity
by: Grigg, Matthew J., et al.
Published: (2020) -
Artemether-lumefantrine versus chloroquine for the treatment of uncomplicated Plasmodium knowlesi malaria (CAN KNOW): an open-label randomized controlled trial
by: Grigg, M, et al.
Published: (2017) -
Limitations of microscopy to differentiate <it>Plasmodium</it> species in a region co-endemic for <it>Plasmodium falciparum</it>, <it>Plasmodium vivax</it> and <it>Plasmodium knowlesi</it>
by: Barber Bridget E, et al.
Published: (2013-01-01) -
Quantification of parasite clearance in Plasmodium knowlesi infections
by: Jeyamalar T. Thurai Rathnam, et al.
Published: (2023-02-01) -
PLASMODIUM KNOWLESI
by: Betta Kurniawan, et al.
Published: (2020-04-01)